Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis

Prostate

Volumn 67, Issue 5, 2007, Pages 536-546

  Mihalyo, Marianne A ^a   Hagymasi, Adam T ^a   Slaiby, Aaron M ^a   Nevius, Erin E ^a   Adler, Adam J ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Dendritic cells; Prostate cancer; T cells; T regulatory cells; Transgenic mice

Indexed keywords

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; IMMUNOLOGICAL TOLERANCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; CELL TRANSFORMATION, NEOPLASTIC; DENDRITIC CELLS; HISTOCYTOCHEMISTRY; KINETICS; MALE; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; ORGAN SIZE; PROSTATIC NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25; T-LYMPHOCYTES, REGULATORY;

EID: 34047213998     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20549     Document Type: Article

References (46)

1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: Moving beyond current vaccines. Nat Med 2004;10(9):909-915.
2. Srivastava PK. Therapeutic cancer vaccines. Curr Opin Immunol 2006;18(2):201-205.
3. Adler AJ. Mechanisms of T cell tolerance and suppression in cancer mediated by tumor-associated antigens and hormones. Curr Cancer Drug Targets 2007;7(1):3-14.
4. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005;55(1):10-30.
5. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000;60(9):2444-2448.
6. Drake CG, Doody AD, Mihalyo MA, Huang CT, Kelleher E, Ravi S, Hipkiss EL, Flies DB, Kennedy EP, Long M, McGary PW, Coryell L, Nelson WG, Pardoll DM, Adler AJ. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005;7(3):239-249.
7. + single positive cells with a class II major histocompatibility complex-restricted receptor. J Exp Med 1994;180(1):25-34.
8. Jung S, Unutmaz D, Wong P, Sano G, De los Santos K, Sparwasser T, Wu S, Vuthoori S, Ko K, Zavala F, Pamer EG, Littman DR, Lang RA. In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 2002;17(2):211-220.
9. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92(8):3439-3443.
10. + T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen presenting cells. J Exp Med 1998;187(10):1555-1564.
11. Higgins AD, Mihalyo MA, McGary PW, Adler AJ. CD4 cell priming and tolerization are differentially programmed by APCs upon initial engagement. J Immunol 2002;168(11):5573-5581.
12. Long M, Higgins AD, Mihalyo MA, Adler AJ. Effector CD4 cell tolerization is mediated through functional inactivation and involves preferential impairment of TNF-alpha and IFN-gamma expression potentials. Cell Immunol 2003;224(2):114-121.
13. Zammit DJ, Cauley LS, Pham QM, Lefrancois L. Dendritic cells maximize the memory CD8 T cell response to infection. Immunity 2005;22(5):561-570.
14. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999;59(13):3128-3133.
15. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001;194(6):823-832.
16. + T Cell Responses. J Exp Med 2003;198(6):889-901.
17. Pasare C, Medzhitov R. Toll-dependent control mechanisms of CD4 T cell activation. Immunity 2004;21(5):733-741.
18. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster BA, Greenberg NM. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55(3):219-237.
19. Gingrich J, Barrios R, Foster B, Greenberg N. Pathologic progression of autochonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 1999;6:1-6.
20. + T cells. J Ex Med 1997;186(2):239-245.
21. Kurts C, Cannarile M, Klebba I, Brocker T. Dendritic cells are sufficient to cross-present self-antigens to CD8 T cells in vivo. J Immunol 2001;166(3):1439-1442.
22. Belz GT, Behrens GM, Smith CM, Miller JF, Jones C, Lejon K, Fathman CG, Mueller SN, Shortman K, Carbone FR, Heath WR. The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J Exp Med 2002;196(8):1099-1104.
23. Scheinecker C, McHugh R, Shevach EM, Germain RN. Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J Exp Med 2002;196(8):1079-1090.
24. Shevach EM. Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med 2001;193(11):F41-F46.
25. Sakaguchi S. Regulatory T cells: Key controllers of immunologic self-tolerance. Cell 2000;101(5):455-458.
26. + T cell-mediated suppression by dendritic cells. Science 2003;299(5609):1033-1036.
27. Kubo T, Hatton RD, Oliver J, Liu X, Elson CO, Weaver CT. Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells. J Immunol 2004;173(12):7249-7258.
28. + T cells: A common basis between tumor immunity and autoimmunity. J Immunol 1999;163(10):5211-5218.
29. Steitz J, Bruck J, Lenz J, Knop J, Tuting T. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic: cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res 2001;61(24):8643-8646.
30. + T cell tolerance induction versus priming is independent of the rate and number of cell divisions. J Immunol 2000;164:649-655.
31. Mihalyo MA, Doody AD, McAleer JP, Nowak EC, Long M, Yang Y, Adler AJ. In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: Implications for adoptive immunotherapy. J Immunol 2004;172(9)5338-5345.
32. Morgan DJ, Kreuwel HT, Fleck S, Levitsky HI, Pardoll DM, Sherman LA. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol 1998;160(2):643-651.
33. Hu J, Kindsvogel W, Busby S, Bailey MC, Shi Y, Greenberg PD. An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. J Exp Med 1993;177:1681-1690.
34. + T cell- and IL-2-dependent mechanism. Immunity 1999;11(4):483-493.
35. + T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol 1996;26(11):2671-2679.
36. Stavely-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci USA 1998;95:1178-1183.
37. + T cell adoptive immunotherapy. Immunity 2000;13(2):265-276.
38. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J, Hemmi S, Hengartner H, Zinkernagel RM. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001;411(6841):1058-1064.
39. Spiotto MT, Yu P, Rowley DA, Nishimura MI, Meredith SC, Gajewski TF, Fu YX, Schreiber H. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via cross-presentation by bone marrow-derived stromal cells. Immunity 2002;17(6):737-747.
40. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003;21:807-839.
41. Higgins AD, Mihalyo MA, Adler AJ. Effector CD4 cells are tolerized upon exposure to parenchymal self-antigen. J Immunol 2002;169:3622-3629.
42. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, Ravetch JV, Steinman RM, Nussenzweig MC. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001;194(6):769-779.
43. Finkelman FD, Lees A, Birnbaum R, Gause WC, Morris SC. Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J Immunol 1996;157(4):1406-1414.
44. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10(9):942-949.
45. + cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005;201(5):779-791.
46. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005;102(51):18538-18543.